Drug details

Aphexda (motixafortide for injection)

type of Hematopoietic Stem Cell Mobilizers

Aphexda (motixafortide) is a hematopoietic stem cell mobilizer indicated for use in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma.

This drug may have the following side effects:

• hives,
• skin redness,
• itching,
• rash,
• back pain,
• flushing,
• numbness and tingling,
• injection site reactions (pain, redness, itching)
• low blood potassium (hypokalemia), and
• nausea.

The following drugs are related to Aphexda, either as a replacement or used together:

• Abecma (idecabtagene vicleucel suspension)
• Alkeran (melphalan)
• Alkeran Injection (melphalan hcl injection)
• Aredia (pamidronate disodium)
• BiCNU (carmustine)
• Kyprolis (carfilzomib)
• Sarclisa (isatuximab-irfc injection)
• Revlimid (lenalidomide)
• Pomalyst (pomalidomide capsules)
• Xpovio (selinexor tablets)
• Tecvayli (teclistamab-cqyv injection)